The FDA approved fam-trastuzumab deruxtecan-nxki for adults with HER2-positive tumors. Social media posts by HCPs regarding product approvals or launches declined by 6% in April compared to March. Health care professionals on social media expressed enthusiasm about the FDA approval of the treatment, with many praising it as a major milestone in precision medicine. The approval also led to discussions about other FDA approvals, including alectinib for certain patients with non-small cell lung cancer and nogapendekin alfa inbakicept-pmln plus BCG for nonmuscle-invasive bladder cancer. Overall, the HCP community reacted positively to the new treatment options and approvals.
Source link
Health care professionals celebrate ‘milestone’ FDA approval for HER2-positive solid tumors
